公开(公告)号：EP1809738B1

公开(公告)日：2014-03-05

申请号：EP05821237.4

申请日：2005-10-31

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services

发明人： CHILDS, Richard, William, Wyatt ,  IGARASHI, Takehito ,  WYNBERG, Jason, Benjamin

IPC分类号： C12N5/0783

CPC分类号： A61K35/17 ,  A61K35/12 ,  A61K45/06 ,  C12N5/0646

摘要： The invention generally relates to a composition comprising an enriched NK cell population. The invention further relates to a method of treating a solid tumor or a hyperproliferative disorder by administering the enriched NK cell population to a mammalian subject in need thereof.

公开(公告)号：EP2638402A2

公开(公告)日：2013-09-18

申请号：EP11844895.0

申请日：2011-11-08

申请人： The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services,

发明人： BOYER, Anne E. ,  LINS, Renato C. ,  KUKLENYIK, Zsuzsanna ,  GALLEGOS-CANDELA, Maribel ,  QUINN, Conrad P. ,  BARR, John R.

IPC分类号： G01N33/68 ,  C12Q1/25 ,  G01N33/543 ,  G01N33/569

CPC分类号： G01N33/56911 ,  C12Q1/527 ,  G01N2333/32 ,  G01N2333/988

摘要： One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples.

公开(公告)号：EP2295999B1

公开(公告)日：2013-09-04

申请号：EP10187731.4

申请日：2006-09-13

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Kocaturk, Ozgur

IPC分类号： G01R33/28 ,  G01R33/36

CPC分类号： G01R33/287 ,  A61B5/055 ,  G01R33/288 ,  G01R33/3692 ,  G01R33/4814

公开(公告)号：EP1756149B1

公开(公告)日：2013-09-04

申请号：EP05754091.6

申请日：2005-05-24

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： KOPECKO, Dennis, J. ,  XU, DeQi

IPC分类号： C12N15/52 ,  C07K14/25 ,  A61K39/112

CPC分类号： A61K39/0283 ,  A61K48/00 ,  A61K2039/522 ,  A61K2039/523 ,  C07K14/25 ,  C12N15/52 ,  Y02A50/484

摘要： The present invention relates to Salmonella typhi Ty21a a comprising core-linked Shigella dysenteriae type 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2; b) DNA encoding S. dysenteriae serotype 1 biosynthesis polypeptides encoded by any one of SEQ ID NOs: 1 and 2; c) DNA encoding variants of the polypeptide encoded by the DNA of (a) or (b), wherein the variants comprise O antigen biosynthesis polypeptide analogs, wherein one or more of the specified amino acids is deleted or replaced, or wherein one or more non-specified amino acids are added without loss of biosynthesis of Shigella dysenteriae serotype 1 O antigen or protective immunological activity of the O antigen biosynthesis gene product; and d) nucleic acid molecules encoding gene products that share at least about 90% sequence identity with the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 2.

公开(公告)号：EP2527427A3

公开(公告)日：2013-03-06

申请号：EP12173266.3

申请日：2004-11-22

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Miura, Masako ,  Shi, Songtao ,  Seo, Byoung-Moo

IPC分类号： C12N5/077 ,  A61K6/00

CPC分类号： A61K35/32 ,  A01N1/02 ,  A01N1/0205 ,  A01N1/0221 ,  A61C8/0006 ,  A61K9/0063 ,  A61L27/3834 ,  A61L27/3865 ,  A61L27/3895 ,  A61L2300/412 ,  A61L2300/64 ,  C12N5/0664

摘要： The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation.

公开(公告)号：EP1180157B1

公开(公告)日：2012-11-28

申请号：EP00939374.5

申请日：2000-05-26

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： MCCART, J., Andrea ,  BARTLETT, David, L. ,  MOSS, Bernard

IPC分类号： C12N15/863 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  A61K2039/5156 ,  C12N2710/24122 ,  C12N2710/24132 ,  C12N2710/24143

公开(公告)号：EP2062023B1

公开(公告)日：2012-10-03

申请号：EP07874019.8

申请日：2007-08-24

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： MOSS, Bernard ,  WYATT, Linda ,  EARL, Patricia

IPC分类号： C12N15/863 ,  C12N15/85 ,  C12N7/00 ,  A61K39/21 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K2039/5256 ,  C12N2710/24111 ,  C12N2710/24141 ,  C12N2710/24143 ,  C12N2710/24152

摘要： The present invention relates to a method of stabilizing an insert in a recombinant vaccinia virus by disrupting a run of 4 or more G or C residues through a substitution that introduces a silent mutation in the run, the length of which is thereby reduced.

公开(公告)号：EP2461825A2

公开(公告)日：2012-06-13

申请号：EP10807108.5

申请日：2010-08-04

申请人： The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services,

发明人： ANDERSON, Larry J. ,  HAYNES, Lia M. ,  TRIPP, Ralph A.

IPC分类号： A61K39/155 ,  C07K14/115 ,  A61K39/12

CPC分类号： C07K14/135 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/555 ,  A61K2039/55505 ,  A61K2039/6081 ,  C07K14/005 ,  C12N2760/18522 ,  C12N2760/18534

摘要： Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.

摘要翻译： 对应于一种或多种RSV G糖蛋白或其类似物的免疫原性多肽作为疫苗的组分提供。 本发明的组合物可用作预防和治疗RSV感染和相关肺或其它疾病的预防和治疗。 本发明的免疫原包括RSV G蛋白的区域，特别是RSV G A2蛋白的氨基酸残基164-176或其类似物。 本发明的免疫原可单独使用或与其它多肽如RSV G蛋白氨基酸残基155-206或其它疫苗例如活RSV疫苗或灭活的RSV疫苗或其免疫原性类似物组合使用。

公开(公告)号：EP1379535B1

公开(公告)日：2012-06-13

申请号：EP01989844.4

申请日：2001-11-01

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： PAVLAKIS, George, N. ,  GRAGEROV, Alexander ,  FELBER, Barbara, K.

IPC分类号： C07H21/02

CPC分类号： C12N15/62 ,  A61K39/00 ,  A61K2039/5256 ,  C07K2319/02 ,  C07K2319/40 ,  C07K2319/75

摘要： The invention relates to nucleic acids (such as DNA immunization plasmids), encoding fusion proteins containing a destabilizing amino acid sequence attached to an amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased by the presence of the destabilizing amino acid sequence. The invention also relates to nucleic acids encoding secreted fusion proteins, such as those containing chemokines or cytokines, and an attached amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased as a result of being attached to the secretory sequence. The invention also relates methods of increasing the immunogenicity of the encoded proteins for use as vaccines or in gene therapy.

公开(公告)号：EP2363143A3

公开(公告)日：2012-02-15

申请号：EP10012380.1

申请日：2004-03-29

申请人： The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services ,  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, DEPARTMENT OF THE ARMY

发明人： Moss, Bernard ,  Earl, Patricia L. ,  Wyatt, Linda ,  Eller, Leigh Anne

IPC分类号： A61K39/12 ,  A61K39/275 ,  A61K39/21 ,  A61K39/285

CPC分类号： C12N15/86 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/005 ,  C12N2710/24143 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/60

摘要： The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.